506 Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer
Jasgit C. Sachdev, Hendrick-Tobias Arkenau, J. R. Infante, et al.·2014·European Journal of Cancer